Evaluation of Tumor Marker Tests Request In A Hospital Setting
Yazarlar (1)
Doç. Dr. Muzaffer KATAR Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (Uluslararası alan indekslerindeki dergilerde yayınlanan tam makale)
Dergi Adı International Journal of Medical Biochemistry
Dergi ISSN 2587-2362 Scopus Dergi
Dergi Tarandığı Indeksler TRDizin, ProQuest, CABI, Türk Medline, EBSCO, Crossref, Open Access
Makale Dili İngilizce Basım Tarihi 12-2020
Cilt / Sayı / Sayfa 4 / 1 / 8–13 DOI 10.14744/ijmb.2020.46220
Makale Linki https://internationalbiochemistry.com/jvi.aspx?un=IJMB-46220&volume=4&issue=1
UAK Araştırma Alanları
Tıbbi Biyokimya
Özet
Objectives Early diagnosis and treatment of oncological disease is extremely important and tumor marker tests are a valuable tool; however, requests for testing should not be used in excess or without sufficient cause. The aim of this study was to analyze and evaluate the appropriateness of requests for tumor marker tests at a single hospital. Methods Tumor marker tests for carcinoembryonic antigen (CEA), cancer antigen (CA) 15-3, CA 19-9, and CA 125 performed by a single biochemistry laboratory between January 1, 2018 and December 31, 2019 were assessed retrospectively. These tumor markers can be used for screening, diagnostic confirmation, estimating prognosis, and monitoring for recurrence. The departments of internal medicine, gastroenterology, endocrine diseases, chest diseases, general surgery, gynecology and obstetrics, and medical oncology were the most common sources of the requests. Results There were 1420 (40%) requests for CEA, 671 (19%) for CA15-3, 868 (25%) for CA 19-9, and 585 (16%) for CA 125 during the study period. A significant difference based on gender was determined in requests for CEA and CA 125 (p< 0.001 and p= 0.033, respectively). In all, 312 (22%) of requests for CEA markers, 202 (30.1%) for CA 15-3, 204 (23.5%) for CA 19-9, and 113 (19.3%) for CA 125 requests were above the reference range. Significant positive correlations were determined between age and CEA, CA 15-3, and CA 19-9 tumor markers (r= 0.262, p< 0.001; r= 0.096, p= 0.013; r= 0.090, p= 0.008, respectively). The preliminary diagnoses supporting the requests included non-specific pain, acute vaginitis, anemia, anxiety …
Anahtar Kelimeler
Carcinoembriogenic antigen | oncology | test request | tumor follow-up | tumor markers
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Scopus 2
Google Scholar 5
Evaluation of Tumor Marker Tests Request In A Hospital Setting

Paylaş